# RNN 1st Gen Model Merck & Company, Inc. Pharmaceutical preparations

Stock predictor AI models:
67.69% successful of 65 deals
$ 77.15 Last close price
at 18-oct-2021


Model's trade recommendations No return for period yet

0.89% Annual return

$198.28B Market Cap

β 0.41  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return -14.91%
52wk Range
Sortino ratio 0.12
Sharpe ratio 0.11
Norm. RMSE 0.62%
Downside risk 8.37%
Volatility 0.00%
  • 2.60 (3.32%) Div (Yield)
  • BUY Analysts consensus recommendation

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Merck & Company, Inc. (MRK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for MRK model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for MRK.

Model is being retrained on a daily basis.

Float 2523M
P/E 13.57
Shares Outstanding 2531M
% Held by Insiders 0.32%
% Held by Institutions 71.83%
EPS (last reported FY) $5.94
EPS (last reported Q) $1.31
EPS, estimated (last reported Q) $1.33
Total revenues $48 B
Net income $7 B